ArticleCirculation. Genomic and precision medicine2025
Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk.
Article in Circulation. Genomic and precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A machine learning-derived aging index for risk stratification and mortality prediction in cardiovascular-kidney-metabolic syndrome: A retrospective cohort study.PLoS medicine · 2026Article
- Challenges of Biomarker Application in Patients with Cardiorenal Syndrome.Biomedicines · 2026Review
- The Cardiometabolic-to-Cancer Axis: Molecular Insights From Cardio-Kidney-Metabolic Syndrome Staging.JACC. CardioOncology · 2026Article
- Development and validation of continuous cardiovascular-kidney-metabolic syndrome severity score (cCKMS-S) complementing CKM staging.Lipids in health and disease · 2026Article
- Beyond the diagnostic threshold: paradigm shift in laboratory medicine from passive reaction to predictive capability.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardio-kidney-metabolic (CKM) disease represents a significant public health challenge. While proteomics-based risk scores (ProtRS) enhance cardiovascular risk prediction, their utility in improving risk prediction for a composite CKM outcome beyond traditional risk factors remains unknown.
methodsWe analyzed 23 815 UK Biobank participants without baseline CKM disease, defined by
resultsThe study sample had a mean age of 56.1 years; 44% were men, and 94% were White. Over a median follow-up of 13.5 years, 3235 and 1407 incident CKM disease events occurred in the training and validation cohorts, respectively. A ProtRS based on the weighted sum of the 238 least absolute shrinkage and selection operator-selected proteins was significantly associated with incident CKM disease risk (subdistribution hazard ratio per 1-SD, 1.87 [95% CI, 1.73-2.03];
conclusionsA ProtRS was independently associated with incident CKM disease risk and improved risk prediction beyond traditional risk factors in a population free of CKM disease at baseline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.